The FDA has allowed a blood plasma treatment for COVID-19 to be administered under an Emergency Use license – but some have decried the move as a “political stunt” as president Trump accuses the
Lutz Bonacker from CSL Behring tells us about the unique aspects of working with plasma-derived medicines and how they have shaped the company’s approach to working with and for patients.
